Skip to main content
Contact Info
Prof. Suresh Thareja
+91-9617605869
Central University of Punjab, Bathinda, Punjab, India
Prof. Suresh Thareja
Qualification
  • Post Doctorate from Georgia State University, Atlanta, USA (2017)
  • Ph.D. in Pharmaceutical Chemistry from Panjab University, Chandigarh, India (2011).
  • M.Pharm. in Pharmaceutical Chemistry from Poona College of Pharmacy, BVU, Pune, India (2007). 
  • B.Pharm. from Hindu College of Pharmacy, MDU, Rohtak, India (2004).
  • DL-101 General course on Intellectual Property Rights by World Intellectual Property Organization, Geneva (2009).
Experience

Teaching Experience: 13 years

  • Professor, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India (2023 -Till date)
  • Associate Professor, Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India (2020 -2023)
  • Assistant Professor, School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur, C.G., India (2012 -2020) 
  • Assistant Professor, G V M College Of Pharmacy Murthal Road Sonipat, Haryana, India (2007- 2008)

Research Experience: 14 years

  • Raman Post-doctoral Fellow, Georgia State University, Atlanta, GA, USA (2016 -2017)
  • Senior Research Fellow (ICMR-SRF), Panjab University, Chandigarh, India (2008 -2011) 

Any Other Experience (Industrial experience): 6.5 Months

Scientific Writer-II, Novartis Healthcare, Hyderabad, Telangana, India (2011- 12)

Research Area
  • Computer aided drug design and Synthesis of novel chemical entities for the treatment of various disorders including Diabetes and Cancer
  • Natural Products modification
  • Molecular docking and 3D-QSAR studies
Research Interests
  • Computer Aided Drug Design
  • Synthesis
  • Nanoformulations
  • Antidiabetic and anticancer Screening
Research Grants/Projects
  • Design, Synthesis and Development of Novel Dual Inhibitors of DPP IV and PTP 1B (DDPI’s) for the Management of Type 2 Diabetes Mellitus (DST-SERB SRG)
  • Design, Synthesis and Evaluation of Novel Chromen based Aromatase Inhibitors for the Treatment of Hormone Dependent Breast Cancer (RSM, CUP, Bathinda)
  • Pre-Clinical Development of Patented Biphenyl-Thiazolidinediones for the Effective Management of Type 2 Diabetes Mellitus (ICMR, New Delhi)
  • Development and Characterization of Natural Biodegradable Polysaccharides Based Mulitparticulate Formulations for Effective Targeting to Colon for the Management of Inflammatory bowel diseases (AICTE, New Delhi)
  • Computer aided design, synthesis and study of novel PTP-1B inhibitors as potential antidiabetic agents (UGC, New Delhi)

 

Professional Affiliation
  • Member, American Chemical Society, USA
  • Life member Indian Pharmacy Graduates' Association (IPGA), India
  • Frontiers Section Editor (Medicinal Chemistry), Anticancer agents in Medicinal Chemistry (IF:2.505)
  • Frontiers Section Editor (Medicinal Chemistry), Letters in Drug Design and Discovery (IF:1.169)
Professional Recognition/Awards/Scholarships
  • Recipient of Research Award (2022) by Central University of Punjab
  • Recognized in the list of top 2% scientists (2022) globally in the report by Stanford University, California
  • Published research findings in Chemical Reviews (Impact factor: 72.087).
  • Recipient of Raman Post-Doctoral Fellowship from UGC, New Delhi, India.
  • Recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR) New Delhi, India.
  • Best Research paper award in IPC-2008 held at New Delhi.
  • Recipient of $1100 for publication in American Chemical Society
  • Felicitated by Governing body (Syndicate) of Panjab University in 2009.
  • First Position with Distinction in M. Pharm (Pharmaceutical Chemistry).
  • Recipient of GATE fellowship for M. Pharm. from AICTE, New Delhi.
Research Collaboration
  • Dr. Akhlesh Jain, Guru Ghasidas Central university, Bilaspur, C.G., India
  • Prof. P. K. Mishra, National Institute for Research in Environmental Health, Bhopal, India
Publications

Papers: 88

1. Thareja, S.;  Verma, S. K.; Jain, A. K.; Kumar, M.; Bhardwaj, T. R., Rational design and synthesis of novel biphenyl thiazolidinedione conjugates as inhibitors of protein tyrosine phosphatase 1B for the management of type 2 diabetes. Journal of Molecular Structure 2023, 1274, 134546.

2. Ratre, P.; Nazeer, N.; Kumari, R.; Thareja, S.;  Jain, B.; Tiwari, R.; Kamthan, A.; Srivastava, R. K.; Mishra, P. K., Carbon-Based Fluorescent Nano-Biosensors for the Detection of Cell-Free Circulating MicroRNAs. Biosensors 2023, 13 (2), 226.

3. Kumar, A.; Singh, A. K.; Singh, H.; Thareja, S.;  Kumar, P., Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Medical Oncology 2023, 40 (1), 1-19.

4. Kulkarni, S.; Singh, Y.; Biharee, A.; Bhatia, N.; Monga, V. D.; Thareja, S., Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors. Journal of Biomolecular Structure and Dynamics 2023, 1-18.

5. Bhatia, N.; Khator, R.; Kulkarni, S.; Singh, Y.; Kumar, P.; Thareja, S., Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer. Current Medicinal Chemistry 2023.

6. Yadav, M.; Singh, A. K.; Kumar, A.; Thareja, S.;  Kumar, P., An insight to Heat shock protein 90: A remedy for multiple problems. Current pharmaceutical design 2022, 28 (32), 2664-2676.

7. Singh, Y.; Sanjay, K. S.; Kumar, P.; Singh, S.; Thareja, S., Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1α inhibitors. Journal of Biomolecular Structure and Dynamics 2022, 1-18.

8. Singh, Y.; Jaswal, S.; Singh, S.; Verma, S. K.; Thareja, S., Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach. Journal of Biomolecular Structure and Dynamics 2022, 1-23.

9. Singh, K.; Biharee, A.; Vyas, A.; Thareja, S.;  Jain, A. K., Recent Advancement of Polymersomes as Drug Delivery Carrier. Current Pharmaceutical Design 2022, 28 (20), 1621-1631.

10. Singh, A. K.; Novak, J.; Kumar, A.; Singh, H.; Thareja, S.;  Pathak, P.; Grishina, M.; Verma, A.; Yadav, J. P.; Khalilullah, H., Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF V600E inhibitors. RSC advances 2022, 12 (46), 30181-30200.

11. Singh, A. K.; Kumar, A.; Thareja, S.;  Kumar, P., Current insights into the role of BRAF inhibitors in treatment of melanoma. Anti-cancer Agents in Medicinal Chemistry 2022.

12. Singh, A. K.; Kumar, A.; Singh, H.; Sonawane, P.; Paliwal, H.; Thareja, S.;  Pathak, P.; Grishina, M.; Jaremko, M.; Emwas, A.-H., Concept of hybrid drugs and recent advancements in anticancer hybrids. Pharmaceuticals 2022, 15 (9), 1071.

13. Ratre, P.; Kulkarni, S.; Das, S.; Liang, C.; Mishra, P. K.; Thareja, S., Medicinal chemistry aspects and synthetic strategies of coumarin as aromatase inhibitors: an overview. Medical Oncology 2022, 40 (1), 41.

14. Ratre, P.; Jain, B.; Kumari, R.; Thareja, S.;  Tiwari, R.; Srivastava, R. K.; Goryacheva, I. Y.; Mishra, P. K., Bioanalytical Applications of Graphene Quantum Dots for Circulating Cell-Free Nucleic Acids: A Review. ACS omega 2022, 7 (44), 39586-39602.

15. Ratre, P.; Chauhan, P.; Bhargava, A.; Tiwari, R.; Thareja, S.;  Srivastava, R. K.; Mishra, P. K., Nano-engineered vitamins as a potential epigenetic modifier against environmental air pollutants. Reviews on Environmental Health 2022.

16. Pauly, I.; Kumar Singh, A.; Kumar, A.; Singh, Y.; Thareja, S.;  Kamal, M. A.; Verma, A.; Kumar, P., Current insights and molecular docking studies of the drugs under clinical trial as RdRp inhibitors in COVID-19 treatment. Current Pharmaceutical Design 2022, 28 (46), 3677-3705.

17. Kumar, H.; Kumar, D.; Kumar, P.; Thareja, S.;  Marwaha, M. G.; Navik, U.; Marwaha, R. K., Synthesis, biological evaluation and in-silico ADME studies of novel series of thiazolidin-2, 4-dione derivatives as antimicrobial, antioxidant and anticancer agents. BMC chemistry 2022, 16 (1), 1-15.

18. Kharyal, A.; Ranjan, S.; Jaswal, S.; Parveen, D.; Gupta, G. D.; Thareja, S.;  Verma, S. K., Research Progress on 2, 4-Thiazolidinedione and 2-Thioxo-4-thiazolidinone Analogues as Aldose Reductase Inhibitors. Journal of Molecular Structure 2022, 133742.

19. Gidwani, B.; Sahu, V.; Namdeo, P.; Tiwari, S.; Tripathi, A.; Pandey, R. K.; Shukla, S. S.; Joshi, V.; Jain, V.; Thareja, S., Nanocarriers For Drug Targeting. Nanoparticles and Nanocarriers Based Pharmaceutical Formulations 2022, 93.

20. Gidwani, B.; Namdeo, P.; Tiwari, S.; Tripathi, A.; Pandey, R. K.; Shukla, S. S.; Joshi, V.; Jain, V.; Thareja, S.;  Vyas, A., Lipoidal Carrier as Drug Delivery System. Nanoparticles and Nanocarriers Based Pharmaceutical Formulations 2022, 273.

21. Das, S.; Kulkarni, S.; Singh, Y.; Kumar, P.; Thareja, S., Selective Estrogen Receptor Modulators (SERMs) for the Treatment of ER+ Breast Cancer: An Overview. Journal of Molecular Structure 2022, 133853.

22. Biharee, A.; Yadav, A.; Jangid, K.; Singh, Y.; Kulkarni, S.; Sawant, D. M.; Kumar, P.; Thareja, S.;  Jain, A. K., Flavonoids as promising anticancer agents: an in silico investigation of ADMET, binding affinity by molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics 2022, 1-12.

23. Angre, T.; Kumar, A.; Singh, A. K.; Thareja, S.;  Kumar, P., Role of Collagen Regulators in Cancer Treatment: A Comprehensive Review. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2022, 22 (17), 2956-2984.

24. Verma, S. K.; Ratre, P.; Jain, A. K.; Liang, C.; Gupta, G. D.; Thareja, S., De novo designing, assessment of target affinity and binding interactions against aromatase: discovery of novel leads as anti-breast cancer agents. Structural Chemistry 2021, 32, 847-858.

25. Verma, S. K.; Kumar, N.; Thareja, S., Gaussian field-based comparative 3D QSAR modelling for the identification of favourable pharmacophoric features of chromene derivatives as selective inhibitors of ALR2 over ALR1. Structural Chemistry 2021, 32, 1289-1298.

26. Singh, Y.; Saklani, S.; Tantra, T.; Thareja, S., Amino acid derived prodrugs: An approach to improve the bioavailability of clinically approved drugs. Current Topics in Medicinal Chemistry 2021, 21 (24), 2170-2183.

27. Mishra, K.; Verma, S. K.; Ratre, P.; Banjare, L.; Jain, A.; Thareja, S.;  Jain, A. K., In silico molecular interaction studies of chitosan polymer with aromatase inhibitor: Leads to letrozole nanoparticles for the treatment of breast cancer. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2021, 21 (9), 1191-1199.

28. Mandavi, S.; Verma, S. K.; Banjare, L.; Dubey, A.; Bhatt, R.; Thareja, S.;  Jain, A. K., A Comprehension into Target Binding and Spatial Fingerprints of Noscapinoid Analogues as Inhibitors of Tubulin. Medicinal Chemistry 2021, 17 (6), 611-622.

29. Jain, A. K.; Sahu, H.; Mishra, K.; Thareja, S., Mannose conjugated starch nanoparticles for preferential targeting of liver cancer. Current Drug Delivery 2021, 18 (3), 369-380.

30. Jain, A. K.; Mishra, K.; Thareja, S., In silico docking of anti cancerous drugs with β-Cyclodextrin polymer as a prominent approach to improve the bioavailability. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2021, 21 (10), 1275-1283.

31. Jain, A.; Mishra, K.; Thareja, S., In silico docking of anti cancerous drugs with?-cyclodextrin polymer as a prominent approach to improve the bioavailability. 2021.

32. Banjare, L.; Singh, Y.; Verma, S. K.; Singh, A. K.; Kumar, P.; Kumar, S.; Jain, A. K.; Thareja, S., Multifaceted 3D-QSAR analysis for the identification of pharmacophoric features of biphenyl analogues as aromatase inhibitors. Journal of Biomolecular Structure and Dynamics 2021, 1-20.

33. Banjare, L.; Jain, A. K.; Thareja, S., Dual aromatase-sulphatase inhibitors (DASIs) for the treatment of hormone dependent breast cancer. Mini Reviews in Medicinal Chemistry 2021, 21 (20), 3144-3165.

34. Verma, S. K.; Thareja, S., An overview on chemistry of natural aldose reductase inhibitors for the management of diabetic complications. Studies in Natural Products Chemistry 2020, 65, 381-429.

35. Ratre, P.; Mishra, K.; Dubey, A.; Vyas, A.; Jain, A.; Thareja, S., Aromatase inhibitors for the treatment of breast cancer: A journey from the scratch. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2020, 20 (17), 1994-2004.

36. Mishra, K.; Ratre, P.; Thareja, S.;  Jain, A. K., Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review. Current pharmaceutical design 2020.

37. Liao, P.; Bhattarai, N.; Cao, B.; Zhou, X.; Jung, J. H.; Damera, K.; Fuselier, T. T.; Thareja, S.;  Wimley, W. C.; Wang, B., Crotonylation at serine 46 impairs p53 activity. Biochemical and biophysical research communications 2020, 524 (3), 730-735.

38. Keerti Mishra, S. K. V.; Ratre, P.; Banjare, L.; Abhishek, J.; Thareja, S., In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry 2020, 20, 00-00.

39. Jain, A. K.; Thareja, S., Solid lipid nanoparticles. Nanomaterials and Environmental Biotechnology 2020, 221-249.

40. Banjare, L.; Verma, S. K.; Jain, A. K.; Thareja, S., Design and pharmacophoric identification of flavonoid scaffold‐based aromatase inhibitors. Journal of Heterocyclic Chemistry 2020, 57 (9), 3483-3492.

41. Verma, S. K.; Yadav, Y. S.; Thareja, S., 2, 4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018). Mini Reviews in Medicinal Chemistry 2019, 19 (7), 591-598.

42. Jain, A. K.; Thareja, S., In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. Artificial cells, nanomedicine, and biotechnology 2019, 47 (1), 524-539.

43. Banjare, L.; Verma, S. K.; Jain, A. K.; Thareja, S., Structure guided molecular docking assisted alignment dependent 3DQSAR study on steroidal aromatase inhibitors (SAIs) as anti-breast cancer agents. Letters in Drug Design & Discovery 2019, 16 (7), 808-817.

44. Banjare, L.; Verma, S.; Jain, A.; Thareja, S., Lead Molecules as Novel Aromatase Inhibitors: In Silico De Novo Designing and Binding Affinity Studies. Letters in Drug Design & Discovery 2019, 16, 1-11.

45. Xin, M.; Ji, X.; De La Cruz, L. K.; Thareja, S.;  Wang, B., Strategies to target the Hedgehog signaling pathway for cancer therapy. Medicinal Research Reviews 2018, 38 (3), 870-913.

46. Liang, C.; Tian, D.; Ren, X.; Ding, S.; Jia, M.; Xin, M.; Thareja, S., The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. European journal of medicinal chemistry 2018, 151, 315-326.

47. Verma, S. K.; Thareja, S., Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors. PLoS One 2017, 12 (4), e0175318.

48. Thareja, S.;  Zhu, M.; Ji, X.; Wang, B., Boron-based small molecules in disease detection and treatment (2013–2016). Heterocyclic Communications 2017, 23 (3), 137-153.

49. Verma, S. K.; Thareja, S., Formylchromone derivatives as novel and selective PTP-1B inhibitors: a drug design aspect using molecular docking-based self-organizing molecular field analysis. Medicinal Chemistry Research 2016, 25 (7), 1433-1467.

50. Verma, S. K.; Thareja, S., Molecular docking assisted 3D-QSAR study of benzylidene-2, 4-thiazolidinedione derivatives as PTP-1B inhibitors for the management of Type-2 diabetes mellitus. RSC advances 2016, 6 (40), 33857-33867.

51. Verma, S. K.; Rajpoot, T.; K Gautam, M.; K Jain, A.; Thareja, S., Design of novel biphenyl-2-thioxothiazolidin-4-one derivatives as potential protein tyrosine phosphatase (PTP)-1B inhibitors using molecular docking study. Letters in Drug Design & Discovery 2016, 13 (4), 295-300.

52. Thareja, S.;  Verma, S. K.; Haksar, D.; Bhardwaj, T. R.; Kumar, M., Discovery of novel cinnamylidene-thiazolidinedione derivatives as PTP-1B inhibitors for the management of type 2 diabetes. RSC advances 2016, 6 (110), 108928-108940.

53. Payra, S.; Saha, A.; Wu, C.-M.; Selvaratnam, B.; Dramstad, T.; Mahoney, L.; Verma, S. K.; Thareja, S.;  Koodali, R.; Banerjee, S., Fe–SBA-15 catalyzed synthesis of 2-alkoxyimidazo [1, 2-a] pyridines and screening of their in silico selectivity and binding affinity to biological targets. New Journal of Chemistry 2016, 40 (11), 9753-9760.

54. Thareja, S.;  Rajpoot, T.; Verma, S. K., Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: a 3D-QSAR study on 6-azasteroids. Steroids 2015, 95, 96-103.

55. Thareja, S., Steroidal 5α-reductase inhibitors: a comparative 3D-QSAR study review. Chemical Reviews 2015, 115 (8), 2883-2894.

56. Suresh Thareja, S. K. V., Shashi Kant Sharma, Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors. Letters in Drug Design & Discovery 2015, 12 (4), 284-291.

57. Saha, A.; Payra, S.; Verma, S. K.; Mandal, M.; Thareja, S.;  Banerjee, S., In silico binding affinity to cyclooxygenase-II and green synthesis of benzylpyrazolyl coumarin derivatives. RSC advances 2015, 5 (122), 100978-100983.

58. Dhumal, B. R.; Bhusari, K. P.; Patra, A.; Thareja, S.;  Jain, N. S., Stability indicating high performance thin layer chromatographic method for the determination of tramadol hydrochloride in pharmaceutical formulation. Journal of Liquid Chromatography & Related Technologies 2015, 38 (10), 1088-1093.

59. Kumar, A.; Kumar Mishra, D.; Gautam, M.; Thareja, S., Computational simulations as preformulation perspective for the delivery of NSAIDS using β-cyclodextrin. Letters in Drug Design & Discovery 2013, 10 (9), 853-858.

60. Gautam, M. K.; Thareja, S., Molecular docking studies of novel arylidene-2, 4-thiazolidinediones as potential aldose reductase inhibitors. Letters in Drug Design & Discovery 2013, 10 (7), 604-612.

61. Thareja, S.;  Kumar, M.; Sinha, V., Self-organizing molecular field analysis of NSAIDs: Assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach. European journal of medicinal chemistry 2012, 53, 76-82.

62. Thareja, S.;  Aggarwal, S.; Bhardwaj, T.; Kumar, M., Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus. Medicinal research reviews 2012, 32 (3), 459-517.

63. Goel, H.; Thareja, S.;  Malla, P.; Kumar, M.; Sinha, V., In silico predicative studies for cytotoxic potential of NSAIDs using self-organizing molecular field analysis. International Journal of Toxicology 2012, 31 (4), 390-396.

64. Goel, H.; Thareja, S.;  Malla, P.; Kumar, M.; R Sinha, V., Quantitative Structural Activity Relationship Studies for In Silico Prediction of In Vitro Cytotoxicity of NSAIDs in Colon Cancer Cell Lines. Letters in Drug Design & Discovery 2012, 9 (8), 755-763.

65. Aggarwal, S.; Thareja, S.;  Bhardwaj, T.; Haupenthal, J.; Hartmann, R.; Kumar, M., Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach. European journal of medicinal chemistry 2012, 54, 728-739.

66. Goel, H.; Sinha, V.; Thareja, S.;  Aggarwal, S.; Kumar, M., Assessment of biological half life using in silico QSPkR approach: A self organizing molecular field analysis (SOMFA) on a series of antimicrobial quinolone drugs. International journal of pharmaceutics 2011, 415 (1-2), 158-163.

67. Aggarwal, S.; Thareja, S.;  Verma, A.; Bhardwaj, T. R.; Kumar, M., QSAR studies on human 5α-reductase inhibitors: unsaturated 3-carboxysteroids. Acta Pol Pharm 2011, 68 (3), 447-452.

68. Thareja, S.;  Verma, A.; Kalra, A.; Gosain, S.; Rewatkar, P. V.; Kokil, G. R., Novel chromeneimidazole derivatives as antifungal compounds: synthesis and in vitro evaluation. Acta Pol Pharm 2010, 67, 423-427.

69. Thareja, S.;  Kokil, G. R.; Aggarwal, S.; Bhardwaj, T. R.; Kumar, M., Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: A three-dimensional quantitative structure–activity relationship study using self-organizing molecular field analysis approach. Chemical and Pharmaceutical Bulletin 2010, 58 (4), 526-532.

70. Thareja, S.;  Aggarwal, S.; Verma, A.; Raj Bhardwaj, T.; Kumar, M., 3D QSAR studies on 1, 3, 4-thiadiazole derivatives: An approach to design novel anticonvulsants. Medicinal Chemistry 2010, 6 (4), 233-238.

71. Thareja, S.;  Aggarwal, S.; Raj Bhardwaj, T.; Kumar, M., Self-Organizing Molecular Field Analysis on Pyridazine Analogues as Protein Tyrosine Phosphatase 1B (PTP 1B) Inhibitors. Letters in Drug Design & Discovery 2010, 7 (6), 395-401.

72. Thareja, S.;  Aggarwal, S.; Malla, P.; Haksar, D.; Raj Bhardwaj, T.; Kumar, M., Saxagliptin: a new drug for the treatment of type 2 diabetes. Mini Reviews in Medicinal Chemistry 2010, 10 (8), 759-765.

73. Thareja, S.;  Aggarwal, S.; Bhardwaj, T. R.; Kumar, M., 3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach. Medicinal Chemistry 2010, 6 (1), 30-36.

74. Thareja, S.;  Aggarwal, S.; Bhardwaj, T.; Kumar, M., Self-organizing molecular field analysis of 2, 4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors. European journal of medicinal chemistry 2010, 45 (6), 2537-2546.

75. Rewatkar, P. V.; Kokil, G. R.; Verma, A.; Thareja, S., Rheumatoid arthritis: a new challenge in coming era. Mini reviews in medicinal chemistry 2010, 10 (2), 98-107.

76. R Kokil, G.; V Rewatkar, P.; Verma, A.; Thareja, S.;  R Naik, S., Pharmacology and chemistry of diabetes mellitus and antidiabetic drugs: a critical review. Current Medicinal Chemistry 2010, 17 (35), 4405-4423.

77. Mehta, N.; Aggarwal, S.; Thareja, S.;  Malla, P.; Misra, M.; Bhardwaj, T. R.; Kumar, M., Synthesis, pharmacological and toxicological evaluation of amide derivatives of ibuprofen. International Journal of Chem Tech Research 2010, 2 (1), 233-238.

78. Kokil, G. R.; Rewatkar, P. V.; Gosain, S.; Aggarwal, S.; Verma, A.; Kalra, A.; Thareja, S., Synthesis and in vitro evaluation of novel 1, 2, 4-triazole derivatives as antifungal agents. Letters in Drug Design & Discovery 2010, 7 (1), 46-49.

79. Gosain, S.; Ircchiaya, R.; Sharma, P. C.; Thareja, S.;  Kalra, A.; Deep, A.; Bhardwaj, T. R., Hypolipidemic effect of ethanolic extract from the leaves of Hibiscus sabdariffa L. in hyperlipidemic rats. Acta Pol Pharm 2010, 67 (2), 179-184.

80. Aggarwal, S.; Thareja, S.;  Verma, A.; Bhardwaj, T. R.; Kumar, M., An overview on 5α-reductase inhibitors. Steroids 2010, 75 (2), 109-153.

81. Aggarwal, S.; Thareja, S.;  Bhardwaj, T. R.; Kumar, M., Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5α-reductase inhibitors. Steroids 2010, 75 (6), 411-418.

82. Aggarwal, S.; Thareja, S.;  Bhardwaj, T.; Kumar, M., Ligand based 3D-QSAR study on a series of steroidal human 5α-reductase inhibitors. Letters in Drug Design & Discovery 2010, 7 (8), 596-601.

83. Aggarwal, S.; Thareja, S.;  Bhardwaj, T.; Kumar, M., 3D-QSAR studies on unsaturated 4-azasteroids as human 5α-reductase inhibitors: a self organizing molecular field analysis approach. European journal of medicinal chemistry 2010, 45 (2), 476-481.

84. Thareja, S.;  Aggarwal, S.; Bhardwaj, T.; Kumar, M., Self organizing molecular field analysis on a series of human 5α-reductase inhibitors: Unsaturated 3-carboxysteroid. European journal of medicinal chemistry 2009, 44 (12), 4920-4925.

85. Sachan, N.; Thareja, S.;  Agarwal, R.; Kadam, S. S.; Kulkarni, V. M., Substituted biphenyl ethanones as antidiabetic agents: synthesis and in-vivo screening. Int J Pharm Tech Res 2009, 1, 625-31.

86. Kumar, M.; Aggarwal, S.; Thareja, S.;  Arora, P.; Malla, P.; Bhardwaj, T. R., Synthesis of Novel 17-Oxo-17a-Aza-D-Homo-3, 5-Seco-Steroids as Potential 5α-Reductase Inhibitors. Journal of the Iranian Chemical Research 2009, 2 (3), 211-219.

87. Thareja, S., Design synthesis and study of novel antidiabetic agents.

88. Raj, A.; Kumar, A.; Singh, A. K.; Singh, H.; Thareja, S.;  Kumar, P., Synthetic methodologies and SAR of quinazoline derivatives as PI3K inhibitors. Anti-cancer agents in medicinal chemistry.

Research Guidance
  • Ph.D. Guidance: 
  • Awarded (02)
  1. Design, synthesis and biological evaluation of novel arylidene-thiazolidinedione derivatives for the management of diabetic complications (Sant Kumar Verma, Ph.D. Awarded, 2019).
  2. Design, synthesis, and evaluation of novel biphenyl analogues as aromatase inhibitors for the treatment of breast cancer (Laxmi, Ph.D. Awarded, 2022)
  • Ongoing (06)
  1. Design, Synthesis and Pharmacological Screening of N-Substituted 2, 4-Thiazolidinedione derivatives as PTP 1B inhibitors for the management of T2DM (Avadh Biharee, Ph.D. Ongoing)
  2. Design, Synthesis, Evaluation and Validation of Triple Nano-Biosensors for the Early Detection of Breast Cancer (Pooja Ratre, Ph.D. Ongoing)
  3. Design, synthesis and biological evaluation of novel Non-steroidal 17β-Hydroxysteroid dehydrogenase (17β-HSD) Antagonists for the Treatment of Poly-Cystic Ovarian Syndrome (PCOS) (Kulkaarni Swanand Sanjay, Ph.D. Ongoing)
  4. Design, Synthesis and Biological Screening of Novel Dual Inhibitors of DPP IV and PTP 1B (DDPI’s) for the Management of Type 2 Diabetes Mellitus (Yogesh, Ph.D. Ongoing)
  5. Design, synthesis, and biological screening of novel Indole analogues as aromatase inhibitors for the treatment of breast cancer (Neha, Ph.D. Ongoing)
  6. Extraction and Isolation of phytoconstituents of Moringa oleifera for the Treatment of Poly-Cystic Ovarian Syndrome (PCOS) (Khushi, Ph.D. Ongoing)
  • M. Pharm. Guidance: 25
Conference/ Workshops/Seminars Attended

University Level:02

Thareja S and Verma S K, “Design, Synthesis and Biological Evaluation of Novel NSubstituted 2, 4-Thiazolidinedione Derivatives as PTP-1B Inhibitors”, “Traditional Medicines and Modern Drug Research for Better Health Care, Bilaspur, C.G (March, 2019). 

Thareja S, “Computer aided drug design”, Training on bioinformatics by CIMS Bilaspur, Bilaspur, C.G, India (Feb, 2020).

National: 11

International: 04 

Thareja S, “Identification of Novel Cinnamylidene Thiazolidinedione Derivatives as PTP 1B Inhibitors for the Management of Type 2 Diabetes Mellitus”, ACS MEDI-EFMC Medicinal Chemistry Frontiers 2017, Philadelphia, USA (June, 2017)

Conference/ Workshops/Seminars Organised
 

 

Peer Recognition
  • Frontiers Section Editor (Medicinal Chemistry), Anticancer agents in Medicinal Chemistry (IF:2.505)
  • Frontiers Section Editor (Medicinal Chemistry), Letters in Drug Design and Discovery (IF:1.169)
Invited Talks/ Resource Person
Invited talk in the Online AICTE -ISTE refresher course held at ISF College of Pharmacy, Moga (2021)
Chairperson, Technical Session, ISFCON International Conference (2021)
Invited talk in the Online AICTE Sponsored Short Term Training Programme (STTP) held at Columbia Institute of Pharmacy, Raipur (2021)
Invited talk in faculty development program held at GLA University, Mathura (2020)
Patent Filed/ Published

PATENT Granted: 01

  • “Synthesis and uses of 5-[4-(2-biphenyl-4-yl-2- oxo-ethoxy)-benzylidene]-thiazolidine-2, 4-dione derivatives” (Patent No.: 382675)

PATENT FILED/PUBLISHED:07

  • "Synthesis and uses of 5-[4-(2-biphenyl-4-yl-2- oxo-ethoxy)-benzylidene]-thiazolidine-2, 4-dione derivatives” (PCT International Publication No. WO 2019/016826).
  • “Dual inhibitors of aldose reductase and PTP 1B, methods of making and uses thereof” (Indian Patent Application No. 201921023832).
  • “Novel (Z)-5-((E)-2-Methyl-3- Phenylallylidene)-2,4-Dioxothiazolidine-3-Carboxylic Acid as Dual Inhibitor of AR and PTP 1B, Synthesis and Uses Thereof” (Indian Patent Application No. 201921024452).
  • “Novel derivatives of (z)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione as inhibitors of PTP 1B"
  • "Novel 3-methyl-1-(4-methylbenzyl) pyrimidine-2,4-diones as inhibitors of DPP-4, their synthesis and uses thereof" (Indian Patent Application No. 202211040050).
  • “Novel (1E,6E)-1-(4-(2-([1,1'-biphenyl]-4-yl)-2-oxoethoxy)-3-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione, its synthesis and uses thereof” (Indian Patent Application No. 202311001450).
  • "Novel Polyphenolic Boron Adducts, Their Synthesis and Uses Thereof"(Indian Patent Application No. 202311006635).
Contribution Towards Institutional Building
Member, Research Park Cell, CUPB
Member, School Board, School of Health Sciences, Central University of Punjab (CUP).
Member, Academic and Administrative Committee, DPSNP, CUPB
Coordinator, AICTE and PCI, DPSNP, CUPB
Citations

H-Index: 20

I-10 index: 34

Total citations:1759

Curricular Development
Member, Curriculum Design and Development Committee, DPSNP, CUPB
Other Significant Achievements

Best Research Paper Award - Self Organizing Molecular Field Analysis On A Novel Class Of Human Protein Tyrosine Inhibitors (H PTP) One B Inhibitors For The Management Of Diabetes Mellitus - IPC-2008 at New Delhi (National)